Clinical & Translational Gastroenterology: Melatonin can reduce the risk of colorectal cancer for the elderly
Globally, colorectal cancer (CRC) is still one of the highest incidence of cancer, and it is also the second major cause of death caused by cancer. According to statistics from the International Cancer Research Agency, about 1.8 million new CRC cases and 900,000 people died in 2018, accounting for about one -tenth of cancer cases and deaths. The incidence and mortality of CRC increased rapidly after the age of 50. In the foreseeable future, due to aging population, this will lead to an increase in global medical burden. Considering that the risk of the elderly with CRC is relatively high, the elderly need effective prevention strategies.
<!–
->
Chemical prevention, even using drugs to block the disease of the disease, has become a attractive strategy to prevent cancer. In recent decades, several non -anti -cancer drugs have been potential to prevent CRC. Melale melatonin is a natural compound, which is mainly secreted by the pine cones of humans and mammals to regulate the rhythm of day and night. Clinically, melatonin is used for short -term treatment of insomnia, such as duration or shift work. Due to the discovery of rhythm disorders is a major factor in the development of cancer, melatonin has attracted great attention in terms of cancer prevention and cancer -assisted therapy. In addition to the important role in regulating the rhythm of day and night, melatonin is also known for its antioxidant, anti -inflammatory, immune regulation and tumor inhibitory activity. Therefore, the purpose of this study is to explore whether the use of melatonin is related to the decrease in the incidence of CRCs in the elderly (over 50 years old).
The researchers conducted a national queue study, which determined from the prescription drug registration database to a total of 58,657 melatonin users who are 50 years old and over. The comparison of hormones is matched in a ratio of 1: 3. The COX regression model is used to calculate the risk ratio and 95% confident interval.
The results of the study found that the incidence of CRC in melatonin users was 10.40 cases per 10,000 people, rather than the incidence of CRCs of not users was 12.82 cases per 10,000 people. We found that there is significant negative correlation between the use of melatonin and CRC risk (OR, 0.82; 95%CI, 0.72–0.92). Trend inspection shows that such a protective effect is significant dose reaction correlation (P <0.001). The decrease in CRC risk has nothing to do with the tumor position and staging during diagnosis. When the age group is layered, the negative correlation exists among individuals 60 and over.
This crowd -based queue study showed that the use of melatonin is related to reducing CRC risks, but the mechanisms need to be further explored.
Primitive source:
Zhang, naiqi mphil. Et al. Use of melatonin is associated with low light of color cancer in older adults.clinical and translational gastroLOGY.2021.
